Jacob Moyer, BS

Jacob Moyer, BS, is a graduate researcher at Mayo Clinic.

Articles by Jacob Moyer, BS

Jacob Moyer, BS, graduate researcher, Mayo Clinic; Mark Tyson II, MD, MPH, urologic oncologist, associate professor, urology, Mayo Clinic Alix School of Medicine

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

ByJacob Moyer, BS,Mark D. Tyson, II, MD, MPH

May 1st 2025

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

ByJacob Moyer, BS

March 19th 2025

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Jacob Moyer, BS

Articles by Jacob Moyer, BS

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Latest Updated Articles

Trending on OncLive

Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial

Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia

QTX3034 Plus Cetuximab Receives FDA Fast Track Designation in KRAS G12D–Mutated CRC